Core Insights - Immunic, Inc. (NASDAQ:IMUX) has experienced a significant share price increase of 24.10% over the past five days as of January 9, 2026, following a review of its 2025 performance and upcoming milestones [2] Group 1: Company Performance and Milestones - The company has completed enrollment in the Phase 3 ENSURE-1 and ENSURE-2 trials for vidofludimus calcium (IMU-838) in relapsing multiple sclerosis (RMS), with 1,121 and 1,100 patients enrolled across over 100 sites in 15 countries [3] - A synchronized top-line readout is anticipated by the end of 2026 to evaluate the therapy's potential in modifying disease progression [3] - Long-term Phase 2 EMPhASIS data confirmed durable disability protection in relapsing-remitting MS (RRMS), with over 92% of patients remaining free of 24-week confirmed disability worsening after up to 5.5 years [4] Group 2: Clinical Trial Results - The Phase 2 CALLIPER trial in progressive MS demonstrated statistically significant reductions in 24-week confirmed disability worsening (24wCDW), indicating neuroprotective effects independent of inflammation [5] Group 3: Product Development and Financing - Management discussed IMU-856, a small molecule modulator targeting Sirtuin 6 (SIRT6), which has shown promising early clinical and preclinical signals for gastrointestinal barrier restoration and weight management [6] - The company plans to expand its oral immunology portfolio, supported by strong financing in 2025, including a $65 million public offering to advance its programs [6] Group 4: Company Focus - Immunic, Inc. is dedicated to developing selective oral immunology therapies aimed at chronic inflammatory and autoimmune diseases, including multiple sclerosis, ulcerative colitis, and Crohn's disease [7]

Core Viewpoint - Immunic, Inc. has successfully closed a registered direct offering of 5,666,667 shares of common stock at a price of $0.90 per share, raising approximately $5.1 million in gross proceeds to fund clinical trials and operations [1][2]. Group 1: Offering Details - The offering was led by Aberdeen Investments and closed on April 10, 2025 [1]. - The gross proceeds from the offering were approximately $5.1 million before deducting commissions and offering expenses [2]. - Titan Partners Group acted as the sole placement agent for the offering [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be used to fund clinical trials, operations, and other general corporate purposes [2]. Group 3: Company Overview - Immunic, Inc. is a biotechnology company focused on developing orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases [5]. - The lead development program, vidofludimus calcium (IMU-838), is in phase 3 and phase 2 clinical trials for multiple sclerosis and has shown therapeutic activity in earlier trials [5]. - Other development programs include IMU-856, targeting gastrointestinal diseases, and IMU-381, which is in preclinical testing [5].

Core Viewpoint - Immunic, Inc. has announced a registered direct offering of 5,666,667 shares of its common stock at a price of $0.90 per share, aiming to raise approximately $5.1 million to fund clinical trials and operations [1][2]. Group 1: Offering Details - The offering is priced at $0.90 per share, with gross proceeds expected to be around $5.1 million before commissions and expenses [1][2]. - The offering is expected to close on or about April 10, 2025, pending customary closing conditions [2]. - Titan Partners Group is acting as the sole placement agent for the offering [3]. Group 2: Company Overview - Immunic, Inc. is a biotechnology company focused on developing orally administered small molecule therapies for chronic inflammatory and autoimmune diseases [6]. - The lead development program, vidofludimus calcium (IMU-838), is in phase 3 and phase 2 clinical trials for multiple sclerosis and has shown therapeutic activity in earlier trials [6]. - Other development programs include IMU-856, targeting gastrointestinal diseases, and IMU-381, which is in preclinical testing [6].

Company Overview - Immunic, Inc. is a biotechnology company focused on developing orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases [1] - The company's lead development program, vidofludimus calcium (IMU-838), is in phase 3 and phase 2 clinical trials for relapsing and progressive multiple sclerosis, respectively [1] - Vidofludimus calcium has demonstrated therapeutic activity in phase 2 trials for relapsing-remitting multiple sclerosis, progressive multiple sclerosis, and moderate-to-severe ulcerative colitis [1] Product Pipeline - Vidofludimus calcium acts as a first-in-class nuclear receptor related 1 (Nurr1) activator, providing neuroprotective effects and additional anti-inflammatory and anti-viral effects by inhibiting dihydroorotate dehydrogenase (DHODH) [1] - IMU-856 targets Sirtuin 6 (SIRT6) to restore intestinal barrier function and regenerate bowel epithelium, with potential applications in gastrointestinal diseases such as celiac disease and inflammatory bowel disease [1] - IMU-381 is a next-generation molecule in preclinical testing aimed at addressing gastrointestinal diseases [1] Upcoming Conferences - Immunic will participate in the American Academy of Neurology (AAN) 2025 Annual Meeting from April 5-9, 2025, in San Diego, California, with management and medical teams available at booth 2233 [3] - At the German Biotech Days 2025 on April 9-10, 2025, Chief Scientific Officer Hella Kohlhof will present on vidofludimus calcium, highlighting its dual benefits of neuroprotection and relapse prevention [3] - The presentation will be part of a symposium titled "All Grown Up? Mature Biotech Companies Present their Progress" on April 9, 2025 [3]